Persönlicher Status und Werkzeuge

Sprachwahl

Publications (1998-2016)

1.  "Key aromatic/hydrophobic amino acids controlling a cross-amyloid peptide interaction versus amyloid self-assembly". Bakou M, Hille K, Kracklauer M, Spanopoulou A, Frost CV, Malideli E, Yan LM, Caporale A, Zacharias M, Kapurniotu A. J. Biol. Chem. 2017 Jul 6. [Epub ahead of print].

2.   "Peptide Inhibitors of the Amyloidogenesis of IAPP: Verification of the Hairpin Binding Geometry Hypothesis". Sivanesam K, Shu I, Huggins KN, Tatarek-Nossol M, Kapurniotu A, Andersen NH, FEBS Lett, 16, 2575-83 (2016).

3.   Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: Evidence for Partial Allosteric Agonism in Comparison to CXCL12". Rajasekaran D, Gröning S, Schmitz C, Zierow S, Drucker N, Bakou M, Kohl K, Mertens A, Lue H, Weber C, Xiao A, Luker G, Kapurniotu A, Lolis EJ, Bernhagen J, J. Biol. Chem. 291, 15881-95 (2016).

4.   "A Hot-Segment-Based Approach for the Design of Cross-Amyloid Interaction Surface Mimics as Inhibitors of Amyloid Self-Assembly". Andreetto E, Malideli E, Yan LM, Kracklauer M, Farbiarz K, Tatarek-Nossol M, Rammes G, Prade E, Neumüller T, Caporale A, Spanopoulou A, Bakou M, Reif B, Kapurniotu A, Angew Chem Int Ed Engl. 54, 13095-100 (2015).

5.   "Development of Accessible Peptidic Tool Compounds To Study the Phosphatase PTP1B in Intact Cells". Meyer C, Hoeger B, Temmerman K, Tatarek-Nossol M, Pogenberg V, Bernhagen J, Wilmanns M, Kapurniotu A, Köhn M., ACS Chem Biol. 21, 769-76 (2014).

6.    „Molecular Characterization of the Hetero-Assembly of beta-Amyloid Peptide with Islet Amyloid Polypeptide”. Yan LM, Velkova A, Kapurniotu A., Curr Pharm Des. 20, 1182-91 (2014).

7.       „Selectively N-Methylated Soluble IAPP Mimics as Potent IAPP Receptor Agonists and Nanomolar Inhibitors of Cytotoxic Self-Assembly of Both IAPP and Abeta40”. Yan LM, Velkova A, Tatarek-Nossol M, Rammes G, Sibaev A, Andreetto E, Kracklauer M, Bakou M, Malideli E, Göke B, Schirra J, Storr M, Kapurniotu A., Angew Chem Int Ed Engl. 52, 10378-83 (2013). 

8.      "The backbone dynamics of the amyloid precursor protein transmembrane helix provides a rationale for the sequential cleavage mechanism of beta-secretase". Pester O, Barrett PJ, Hornburg D, Hornburg P, Pröbstle R, Widmaier S, Kutzner C, Dürrbaum M, Kapurniotu A, Sanders CR, Scharnagl C, Langosch D., J Am Chem Soc. 135,1317-29 (2013).

9.      "Cross-Amyloid Interaction of Aß and IAPP at Lipid Membranes". Seeliger J, Evers F, Jeworrek C, Kapoor S, Weise K, Andreetto E, Tolan M, Kapurniotu A., Winter R. Angew. Chem. Int. Ed. Engl. 51, 679-83 (2012).

10.      "Shedding light on Alzheimer`s ß-amyloid aggregation with chemical tools". Kapurniotu A., Chembiochem. 13, 27-9 (2012).

11.   "Terminating the amyloid zipper by design". Kapurniotu A., Angew Chem Int Ed Engl. 50, 11293-4 (2011).

12.  "Designed hairpin peptides interfere with amyloidogenesis pathways: fibril formation and cytotoxity inhibition, interception of the preamyloid state". Huggins KN, Bisaglia M, Bubacco L, Tatarek-Nossol M, Kapurniotu A., Andersen NH. Biochemistry. 50, 8202-12 (2011).

13.  "Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polypeptide". Rezaei-Ghaleh N, Andreetto E, Yan LM, Kapurniotu A., Zweckstetter M. PLoS One. 6, 20289 (2011).

14.  "Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Abeta40 amyloid formation and cytotoxicity." Andreetto, E., Yan, L-M., Caporale, A., Kapurniotu A.; ChemBioChem. 12, 1313-22, (2011).

15.  "MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism." Kraemer S, Lue H, Zernecke A, Kapurniotu A, Andreetto E, Frank R, Lennartz B, Weber C, Bernhagen J., FASEB J. 25, 894-906 (2011).

16.  "Identification of Hot Regions of the Abeta-IAPP Interaction Interface As High Affinity Binding Sites in both Cross- and Self-Association" Erika Andreetto, Li-Mei Yan, Marianna Tatarek-Nossol, Aleksandra Velkova, Ronald Frank, A. Kapurniotu, Angew Chem Int Ed Engl. 49, 3081-3085 (2010).

17.  "Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin" D. Sellin, L.-M.Yan, A. Kapurniotu, R.Winter, Biophys. Chem. 150, 73-79 (2010).

18.  “Exploiting Cross-Amyloid Interactions to Inhibit Protein Aggregation but not Function: Nanomolar Affinity Inhibition of Insulin Aggregation by an IAPP mimic” A. Velkova, M. Tatarek-Nossol, E. Andreetto, A. Kapurniotu Angew Chem Int Ed Engl. 47, 7114-7118 (2008).

19.  “Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte reqruitment” C. Weber, S. Kraemer, M. Drechsler, H. Lui, R. Koenen, A. Kapurniotu, A. Zernecke, J. Bernhagen Proc. Natl. Acad. Sci. USA 105, 16278-16283 (2008).

20.  “Cytotoxicity of Insulin within its Self-assembly and Amyloidogenic Pathways” S. Grudzielanek, A. Velkova, A. Shukla, V. Smirnovas, M. Tatarek-Nossol, H. Rehage, A. Kapurniotu, Winter R. J. Mol. Biol., 370, 372-84 (2007).

21.  “Designed IAPP Mimic Blocks Ab Cytotoxic Self-Assembly: Cross-Suppression of Amyloid Toxicity of Ab and IAPP Suggests a Molecular Link between Alzheimer’s Disease and Type 2 Diabetes” L.-M. Yan, A. Velkova, M. Tatarek-Nossol, E. Andreetto, A. Kapurniotu Angew Chem Int Ed Engl. VIP 46, 1246-1252 (2007).

22.  “Design of a mimic of non-amyloidogenic and bioactive IAPP as a nanomolar affinity inhibitor of IAPP fibrillogenesis and cytotoxicity” L.-M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, A. Kapurniotu Proc. Natl. Acad. Sci. USA, 103, 2046-2051 (2006).

23.  "A novel drug-eluting stent coated with an integrin-binding cRGD peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells" R. Blindt, F. Vogt, I. Astafieva, C. Fach, N. Krott, B. Seitz,  A. Kapurniotu, C. Kwok, M. Dewor, M. Hristov,  A. Bosserhoff,  J. Bernhagen, P. Hanrath, R. Hoffmann, C. Weber J. Am. Coll. Cardiol. 47, 1786-95 (2006).

24.  “Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity” H. Lue, A. Kapurniotu, G. Fingerle-Rowson, T. Roger, L. Leng, M. Thiele, T. Calandra, R. Bucala, J. Bernhagen Cell Signal., 18, 688-703 (2005).

25.  “Macrophage migration inhibitory factor (MIF) increases neuronal delayed rectifier K+ current” T. Matsuura, C. Sun, L. Leng, A. Kapurniotu, J. Bernhagen, R. Bucala, A. E. Martynyuk, C. Sumners J. Neurophysiol., 95, 1042-1048 (2005).

26.  “Inhibition of IAPP amyloid fibril formation and apoptotic cell death by a designed IAPP amyloid core-containing hexapeptide”, M. Tatarek-Nossol, L.M. Yan, A. Schmauder, K. Tenidis, G. Westermark A. Kapurniotu Chem. Biol., 12, 797-809 (2005).

27.  “Targeting a-synuclein in Parkinson’s disease”, A. Kapurniotu Chem. Biol., 11, 1476-77 (2004) (Preview).

28.  “Contribution of conformationally constrained calcitonin analogues to the understanding of the structural and conformational requirements of calcitonin bioactivity and to the design of potent agonists”, A. Kapurniotu Curr. Med. Chem., 11, 2577-97 (2004) (Review).

29.  “A sixteen residue peptide fragment of macrophage migration inhibitory factor, MIF(50-65), exhibits redox activity and has MIF-like biological functions”, M. T. Nguyen, J. Beck, H. Lue, R. Kleemann, P. Koolwijk, A. Kapurniotu, J. Bernhagen. J. Biol. Chem. 278, 33654-71 (2003).

30.  “Conformational restriction via cyclization in b-amyloid peptide Ab(1-28) leads to an inhibitor of Ab(1-28) amyloidogenesis and cytotoxicity”, A. Kapurniotu, A. Buck, M. Weber, A. Schmauder, T. Hirsch, J. Bernhagen, M. Tatarek-Nossol. Chem. Biol. 10, 149-159 (2003).

31.  „Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity”, A. Kapurniotu, A. Schmauder, K. Tenidis. J. Mol. Biol., 315, 339-350 (2002).

32.  „Side-chain lactam-bridge conformational constrains differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues“, J. W. Taylor, Q. K. Jin, M. Sbacchi, L. Wang, P. Belfiore, M. Garnier, A. Kazantzis, A. Kapurniotu, P. F. Zaratin, M. A. Scheideler. J. Med. Chem., 45, 1108-1121 (2002).

33.  „Conformationally constrained human calcitonin (hCt) analogues reveal a critical role of sequence 17-21 for the oligomerization state and bioactivity of hCt“, A. Kazantzis, M. Waldner, J. W. Taylor, A. Kapurniotu. Eur. J. Biochem., 269, 780-791 (2002).

34.  „Amyloidogenicity and cytotoxicity of islet amyloid polypeptide (IAPP)“, A. Kapurniotu. Biopolymers, 60, 438-59 (2001) (Review).

35.  „Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP)“, M. Krampert, J. Bernhagen, J. Schmucker, A. Horn, A. Schmauder, H. Brunner, W. Voelter, & A. Kapurniotu. Chem. Biol., 7, 855-871 (2000).

36.  „Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1“, R. Kleemann, A. Hausser, G. Geiger, R. Mischke, A. Burger-Kentischer, O. Flieger, F.-J. Johannes, T. Roger, T. Calandra, A. Kapurniotu, M. Grell, D. Finkelmeier, H. Brunner, & J. Bernhagen. Nature, 408, 211-216 (2000).

37.  „Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor (MIF) production in monocytes“, M. Schmidt-Supprian, C. Murphy, B. White, M. Lawler, A. Kapurniotu, W. Voelter, O. Smith, J. Bernhagen. Eur. Cytokine Netw., 11, 3 (2000).

38.  „Identification of a Penta- and Hexapeptide of Islet Amyloid Polypeptide (IAPP) with Amyloidogenic and Cytotoxic Properties“, K. Tenidis, M. Waldner, J. Bernhagen, W. Fischle, M. Bergmann, M. Weber, M.-L. Merkle, W. Voelter, H. Brunner, A. Kapurniotu, J. Mol. Biol., 295, 1055-1071 (2000).

39.  „Rational design, confomational studies and bioactivity of novel, highly potent, conformationally constrained calcitonin analogues“, A. Kapurniotu, R. Kayed, J. W. Taylor, W. Voelter, Eur. J. Biochem., 265, 606-618 (1999).

40.  "Advanced glycation end products in deposited proteins: detection and reversal“, Y. Al-Abed, A. Kapurniotu, R. Bucala, Methods Enzymol., 309, 152-72 (1999) (Review).

41.  24. „Characterization of catalytic center mutants of macrophage migration inhibitory factor (MIF) and comparison to C81S MIF“, R. Kleemann, A. Kapurniotu, R. Mischke, J. Held, J. Bernhagen, Eur. J. Biochem., 261, 753-766 (1999).

42.  „Conformational transitions of islet amyloid polypeptide in amyloid formation in vitro“ R. Kayed, J. Bernhagen, N. Greenfield, K. Sweimeh, H. Brunner, W. Voelter, A. Kapurniotu, J. Mol. Biol., 287, 781-796 (1999).

43.  „Model studies of the Maillard reaction of Arg-Lys with D-glucose“, Y.Al-Abed, D. Callaway, A. Kapurniotu, T. Holak, W. Voelter, R. Bucala, Polisch J. Chem., 73, 117-123 (1999).

44.  „Specific reduction of insulin disulfides by macrophage migration inhibitory factor (MIF) with glutathione and dihydrolipoamide: potential role in cellular redox processes“, R. Kleemann, R. Mischke, A. Kapurniotu, H. Brunner, J. Bernhagen, FEBS Lett., 430, 191-196 (1998).

45.  „Disulfide Analysis Reveals a Role for Macrophage Migration Inhibitory Factor (MIF) as Thiol-protein Oxidoreductase“, R. Kleemann, A. Kapurniotu, R. W. Frank, A. Gessner, R. Mischke, S. Jüttner, H. Brunner, J. Bernhagen., J. Mol. Biol., 280, 85-102 (1998).

46.  „Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide (IAPP)“, A. Kapurniotu, J. Bernhagen, N. Greenfield, S. Teichberg, R.W. Frank, Y. Al-Abed, R. Bucala, Eur. J. Biochem., 251, 208-216 (1998).